|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We are presenting an electrochemical immunosensor for the determination of Galectin-3 (Gal-3), a biomarker of heart failure.
|
29096363 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation.
|
30067817 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 overexpression and secretion is associated with several diseases and is extensively studied in the context of fibrosis, heart failure, atherosclerosis and diabetes mellitus.
|
29344292 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cardiac (NT-proBNP, cTnI, sST2,Gal-3) and inflammatory (IL-6,IL-8) biomarkers were determined in plasma collected from 12 paediatric patients and 7 adult patients with HF, before and at 4 h,1,3,7,14 and 30 days after VAD implant.
|
30040920 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 has been implicated in cardiac and renal fibrosis and serves as a prognostic clinical indicator in heart failure.
|
29417184 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (GAL-3), a beta galactoside binding lectin, is closely associated with myocardial infarction (MI), myocardial fibrosis and heart failure.
|
30355930 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications.
|
29153203 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
A positive correlation between NGAL and galectin-3 in HF patients was found, revealing a potential association between renal injury and myocardial fibrosis and remodeling in HF.
|
30511581 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To determine this, we prospectively analyzed data from 9,148 Atherosclerosis Risk in Communities (ARIC) Study participants with measured plasma galectin-3 levels (baseline, visit 4, 1996-98) and without prevalent chronic kidney disease (CKD) or heart failure.
|
28865675 |
2018 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Galectin-3 (Gal-3) and suppression of tumorigenicity 2 (ST2) induce fibrotic alterations in severe MR and heart failure.
|
29896861 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Studies have evaluated the association of galectin-3 and outcome in patients with heart failure.
|
30018673 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46).
|
30573026 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The alteration of the balance between antioxidant systems and reactive oxygen species production could be a new pathogenic mechanism by which Gal-3 induces cardiac damage in HF.
|
29674526 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
|
29844319 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure.
|
28525549 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure.
|
29229724 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (sST2) are the only novel HF biomarkers that are included in the ACC/AHA HF guidelines, but their clinical utility still needs to be demonstrated.
|
29663841 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 is an emerging biomarker for risk stratification in patients with heart failure.
|
28942393 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study evaluates the prognostic value of repeated time-dependent galectin-3 measurements in acute HF patients.
|
29187387 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), indicating cardiac fibrosis, is a documented biomarker of prognosis in HF.
|
28318874 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study investigated whether multidisciplinary disease management programs (MDPs) exert the same effects in heart failure (HF) patients across risk levels stratified by galectin-3 (Gal-3) level and what factors are associated with inadequate effectiveness of MDP.
|
27443525 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using a random-effects meta-analysis, we found an HR of 1.10 (95% CI 1.05 to 1.14) for all-cause mortality, 1.22 (95% CI 1.05 to 1.39) for CVD mortality, and 1.12 (95% CI 1.04 to 1.21) for HF risk for each 1 SD increase in galectin-3 level.
|
28247849 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased galectin-3 plasma concentration has been linked to an unfavorable outcome in patients with heart failure or atrial fibrillation (AF).
|
29118378 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF).
|
29180917 |
2017 |